VXRT News and Press, Vaxart Inc. From 06/02/22

Results support safety and immunogenicity of the vaccine candidate in the highly vulnerable elderly population Preliminary boost study data also reported Norovirus has been estimated to cost the United States $10.6 billion annually SOUTH SAN FRANCISCO, Calif., June...

SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a fire...

A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in the publication SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Science Translational Medicine ha...

Vaxart (NASDAQ: VXRT) has been involved in the coronavirus vaccine race since the beginning. It's developing what could be a game-changing option: a vaccine in pill form. That's why this biotech player has been one to watch. That potential product is now involved in phase 2 stud...

Vaxart (NASDAQ:VXRT) announced that it is retaining Fuad Ahmad, a partner at FLG, a CFO services and board advisory consulting firm, as its interim CFO and a non-employee consultant. The company is conducting its search for a CFO. As of May 10, 2022, Andrei Floroiu ceased to serve a...

Upstart Holdings (UPST) -54% on Q1 earnings release. GoodRx Holdings (GDRX) -35% on Q1 earnings release. Bausch Health Companies (BHC) -33% on Q1 earnings release. Peloton Interactive (PTON) -24% on FQ3 earnings release. Novavax (NVAX) -2...

Vaxart press release (NASDAQ:VXRT): Q1 GAAP EPS of -$0.20 misses by $0.04. Revenue of $0.09M (-82.4% Y/Y) misses by $0.04M. Cash, equivalents and available-for-sale debt securities of $157.0 million, compared to $182.7 million as of December 31, 2021. The decrease was primarily...

Data from COVID-19 Phase II study and norovirus Phase IB study are expected in 2022 Ended the 1 st Quarter with $157.0 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Decelerating momentum and limited profitability prospects make these stocks analysts hate. Bed Bath & Beyond ( BBBY ): The meme stock continues to burn cash due to supply chain problems. Netflix ...

Many companies that successfully developed effective coronavirus vaccines are reaping the benefits and generating millions -- sometimes billions -- in sales from their products. However, other players are still looking to get in the game. Two notable companies still hoping to make a den...